-
-
-
- New research partnerships with world-leading institutions University of Bern, University Hospital of Bern and Lausanne University Hospital
- Non-dilutive funding will enable the development of therapies targeting lncRNA for cardiomyopathy and squamous cell carcinoma
LAUSANNE, Switzerland and SAN DIEGO – May 3, 2022 — HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced that Innosuisse, the Swiss Innovation Agency, is supporting two research collaboration projects between HAYA and the University of Bern, University Hospital of Bern and Lausanne University Hospital. Innosuisse is funding 50 percent of the total project costs of approximately CHF 3.1 million (US$3.3 million).
-
-
